Reduced Expression of β2 Integrin Genes in Rat Peripheral Leukocytes by Inhibiting Postprandial Hyperglycemia

β₂ integrins (CD11s/CD18) promote the attachment of leukocytes to vascular endothelial cells. We performed in this study sucrose loading to rats with moderate postprandial hyperglycemia with/without once-daily dosing of the α-glucosidase inhibitor, miglitol, for 4 days under 4-h fasting conditions. The streptozotocin (STZ)-treated rats showed moderate postprandial hyperglycemia on days 1 and 4. The gene expression was higher for CD11a with fasting and 3-h postprandial on day 1, and with fasting on day 4, for CD11b with fasting on day 1 and 3-h postprandial on day 4, and for CD18 with fasting on days 1 and 4 in peripheral leukocytes from the STZ-treated rats than in peripheral leukocytes from the saline-treated rats. Miglitol reduced postprandial hyperglycemia and the gene expression of CD11a with fasting and of CD11b 3-h postprandial on day 4. These results indicate that inhibiting postprandial hyperglycemia reduced the mRNA expression of β₂ integrins in peripheral leukocytes of moderately postprandial hyperglycemic rats.     

以甘油为唯一碳源的氧化葡糖杆菌适应性驯化及催化合成米格列醇中间体6NSL

氧化葡糖杆菌(Gluconobacter oxydans)来源的山梨醇脱氢酶可催化N-羟乙基葡萄糖胺合成6-脱氧-6-氨基(N-羟乙基)-α-L-呋喃山梨糖,即合成降血糖药物米格列醇的关键中间体。本文采用适应性驯化策略,以甘油为唯一碳源,通过40 g/L、60 g/L、80 g/L和100 g/L甘油梯度连续传代培养,筛选获得了一株以甘油为碳源的高活力菌株G.oxydans A-3-D,扫描电镜结果表明该细胞表面褶皱较原始菌株有显著增加。在80 g/L甘油培养基摇瓶培养24 h后,菌体浓度为4.58 g DCW/L,山梨醇脱氢酶的发酵体积酶活与比酶活分别为原始菌株G.oxydans ZJB-605的1.3倍及1.5倍。此外,在摇瓶培养条件下对影响催化反应进程的关键因素进行了考查,结果表明在摇瓶体系中,G.oxydans A-3-D的最适催化反应条件为80.0 g/L底物、2.0 g DCW/L菌体细胞、20 mmol/L Mg~(2+)浓度,15℃反应48 h后底物转化率达到90.8%,6NSL累积浓度为72.6 g/L,较G.oxydans ZJB-605有显著提升。     

具有α-葡糖苷酶抑制作用的抗糖尿病药物

α -葡糖苷酶抑制剂是一类具有糖结构的新型抗糖尿病药物 ,已经被广泛用于临床 ,包括阿卡波糖、伏格列波糖和米格列醇。这类药物可以明显降低Ⅱ型糖尿病人餐后血糖水平 ,减少糖尿病并发症的发生。本文简要综述了这类药物的发现、制备和作用机制及药效学、药动学和临床疗效等。     

氧化葡萄糖酸菌转化制备米格列醇关键中间体

米格列醇作为一种新型α－葡糖苷酶抑制剂,能够有效治疗Ⅱ型糖尿病,并已迅速成为首选药物。葡萄糖酸菌细胞膜上含有多种脱氢酶,能够催化一系列重要产物的微生物转化,米格列醇就是其中之一。本文将详细说明不同的微生物转化过程,并进行比较。     

Interaction of antidiabetic α‐glucosidase inhibitors and gut bacteria α‐glucosidase

Carbohydrate hydrolyzing α‐glucosidases are commonly found in microorganisms present in the human intestine microbiome. We have previously reported crystal structures of an α‐glucosidase from the human gut bacterium Blaubia (Ruminococcus) obeum (Ro‐αG1) and its substrate preference/specificity switch. This novel member of the GH31 family is a structural homolog of human intestinal maltase‐glucoamylase (MGAM) and sucrase–isomaltase (SI) with a highly conserved active site that is predicted to be common in Ro‐αG1 homologs among other species that colonize the human gut. In this report, we present structures of Ro‐αG1 in complex with the antidiabetic α‐glucosidase inhibitors voglibose, miglitol, and acarbose and supporting binding data. The in vitro binding of these antidiabetic drugs to Ro‐αG1 suggests the potential for unintended in vivo crossreaction of the α‐glucosidase inhibitors to bacterial α‐glucosidases that are present in gut microorganism communities. Moreover, analysis of these drug‐bound enzyme structures could benefit further antidiabetic drug development.